Cargando…
Development of T-cell engagers selective for cells co-expressing two antigens
T cell-engaging bispecific antibodies (TCEs) are clinically effective treatments for hematological cancers. While the utility of TCEs in solid malignancies is being explored, toxicities arising from antigen expression on normal tissues have slowed or halted several clinical trials. Here, we describe...
Autores principales: | Dicara, Danielle M., Bhakta, Sunil, Go, Mary Ann, Ziai, James, Firestein, Ron, Forrest, Bill, Gu, Chen, Leong, Steven R., Lee, Genee, Yu, Shang-Fan, Polson, Andrew G., Agard, Nicholas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553182/ https://www.ncbi.nlm.nih.gov/pubmed/36206404 http://dx.doi.org/10.1080/19420862.2022.2115213 |
Ejemplares similares
-
High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants
por: DiCara, Danielle M., et al.
Publicado: (2018) -
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Becker, Scott A., et al.
Publicado: (2023) -
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
por: De Bousser, Elien, et al.
Publicado: (2021) -
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023) -
Supramolecular Peptide Nanofibers Engage Mechanisms
of Autophagy in Antigen-Presenting Cells
por: Rudra, Jai S., et al.
Publicado: (2017)